Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Hexner

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
Blood|September 14, 2019
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, et al.
Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Nature Cancer|January 12, 2024
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trialStephen J Bagley, Zev A Binder, Lamia Lamrani, et al.
Haematologica|August 6, 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studiesRuben A Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood|September 15, 2016
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factorsShernan G Holtan, Nandita Khera, John E Levine, et al.
Blood Advances|May 26, 2023
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host diseaseMonzr M Al Malki, Kaitlyn London, Janna Baez, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
Blood|September 14, 2019
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, et al.
Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Nature Cancer|January 12, 2024
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trialStephen J Bagley, Zev A Binder, Lamia Lamrani, et al.
Haematologica|August 6, 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studiesRuben A Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, et al.
Blood Advances|April 19, 2024
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHDAaron Etra, Najla El Jurdi, Nikolaos Katsivelos, et al.
Blood|September 15, 2016
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factorsShernan G Holtan, Nandita Khera, John E Levine, et al.
Blood Advances|May 26, 2023
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host diseaseMonzr M Al Malki, Kaitlyn London, Janna Baez, et al.
Pageof 6